Press Release Details

View all news

Quest Diagnostics adds Helen Torley to Board of Directors


SECAUCUS, N.J., May 17, 2018 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced that Helen I. Torley was elected to serve as a director at the company's 2018 Annual Meeting of Stockholders, expanding the Board of Directors to 10 members.

Quest Diagnostics Incorporated logo. (PRNewsFoto/Quest Diagnostics Incorporated)

Dr. Torley has served since 2014 as President, Chief Executive Officer and director of Halozyme Therapeutics, Inc., a biotechnology company focused on developing and commercializing novel cancer therapies that target the tumor microenvironment.

"As the CEO of a biotechnology company, Helen will bring a unique perspective on science and innovation to our Board," said Steve Rusckowski, Chairman, President and CEO, Quest Diagnostics. "Under her leadership at Halozyme, revenues more than quintupled and market value nearly doubled over a four year period.  Her deep healthcare experience will strengthen our Board and bolster our efforts to accelerate growth and drive operational excellence."

Daniel C. Stanzione, Ph.D., Lead Independent Director of Quest Diagnostics, added: "As a physician with strong business experience in various healthcare roles and organizations, Helen brings expertise in industry management, strategic planning and operations that will be beneficial to our company. We are delighted that she will serve on our Board."

Prior to joining Halozyme, Dr. Torley served as Executive Vice President and Chief Commercial Officer for Onyx Pharmaceuticals; as Vice President and General Manager of the US Bone Health and Nephrology businesses, as well as in other management positions, at Amgen Inc.; and in various senior management positions at Bristol-Myers Squibb and Sandoz/Novartis; and was in medical practice as a senior registrar in rheumatology at the Royal Infirmary in Glasgow, Scotland.

About Quest Diagnostics 

Quest Diagnostics empowers people to take action to improve health outcomes. Derived from the world's largest database of clinical lab results, our diagnostic insights reveal new avenues to identify and treat disease, inspire healthy behaviors and improve health care management. Quest annually serves one in three adult Americans and half the physicians and hospitals in the United States, and our 45,000 employees understand that, in the right hands and with the right context, our diagnostic insights can inspire actions that transform lives.

Cision View original content with multimedia:

SOURCE Quest Diagnostics

Denny Moynihan, Quest Diagnostics (Media): 973-520-2800; Shawn Bevec, Quest Diagnostics (Investors): 973-520-2900

Categories: Press Releases
View all news